Identification of a Five-Gene Signature and Establishment of a Prognostic Nomogram to Predict Progression-Free Interval of Papillary Thyroid Carcinoma

被引:28
作者
Wu, Mengwei [1 ]
Yuan, Hongwei [1 ]
Li, Xiaobin [1 ]
Liao, Quan [1 ]
Liu, Ziwen [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Gen Surg, Beijing, Peoples R China
来源
FRONTIERS IN ENDOCRINOLOGY | 2019年 / 10卷
关键词
TCGA; GEO; papillary thyroid carcinoma; progression-free interval; nomogram; BETA RECEPTOR; CELL-PROLIFERATION; CANCER; GENE; EXPRESSION; NODULES; GROWTH; FXYD6; LIVER; OSTEOSARCOMA;
D O I
10.3389/fendo.2019.00790
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The incidence of papillary thyroid carcinoma (PTC) is high and increasing worldwide. Although prognosis is relatively good, it is important to select the minority of patients with poorer prognosis to avoid side effects associated with unnecessary over-treatment in low-risk patients; this requires accurate prognostic predictions. Materials and Methods: Six PTC expression datasets were obtained from the gene expression omnibus (GEO) database. Level 3 mRNA expression and clinicopathological data were obtained from The Cancer Genome Atlas Thyroid Cancer (TCGA-THCA) database. Through integrated analysis of these datasets, highly reliable differentially-expressed genes (DEGs) between tumor and normal tissue were identified and lasso Cox regression was applied to identify DEGs related to the progression-free interval (PFI) and to establish a prognostic gene signature. The performance of a five-gene signature was evaluated based on a Kaplan-Meier curve, receiver operating characteristic (ROC), and Harrell's concordance index (C-index). Multivariate Cox regression analysis was used to identify factors associated with PTC prognosis. Finally, a prognostic nomogram was established based on the TCGA-THCA dataset. Results: A novel five-gene signature was established to predict the PTC PFI, which included PLP2, LYVE1 , FABP4, TGFBR3, and FXYD6, and the ROC curve and C-index showed good performance in both training and validation datasets. This could classify patients into high- and low-risk groups with distinct PFIs and differentiate PTC tumors from normal tissue. Univariate Cox regression revealed that this signature was an independent prognostic factor for PTC. The established nomogram, incorporating the prognostic gene signature and clinical parameters, was able to predict the PFI with high efficiency. The gene signature-based nomogram was superior to the American Thyroid Association (ATA) risk stratification to predict PTC PFI. Conclusions: Our study identified a five-gene signature and established a prognostic nomogram, which were reliable in predicting the PFI of PTC; this could be beneficial for individualized treatment and medical decision making.
引用
收藏
页数:21
相关论文
共 68 条
  • [1] Integrated Genomic Characterization of Papillary Thyroid Carcinoma
    Agrawal, Nishant
    Akbani, Rehan
    Aksoy, B. Arman
    Ally, Adrian
    Arachchi, Harindra
    Asa, Sylvia L.
    Auman, J. Todd
    Balasundaram, Miruna
    Balu, Saianand
    Baylin, Stephen B.
    Behera, Madhusmita
    Bernard, Brady
    Beroukhim, Rameen
    Bishop, Justin A.
    Black, Aaron D.
    Bodenheimer, Tom
    Boice, Lori
    Bootwalla, Moiz S.
    Bowen, Jay
    Bowlby, Reanne
    Bristow, Christopher A.
    Brookens, Robin
    Brooks, Denise
    Bryant, Robert
    Buda, Elizabeth
    Butterfield, Yaron S. N.
    Carling, Tobias
    Carlsen, Rebecca
    Carter, Scott L.
    Carty, Sally E.
    Chan, Timothy A.
    Chen, Amy Y.
    Cherniack, Andrew D.
    Cheung, Dorothy
    Chin, Lynda
    Cho, Juok
    Chu, Andy
    Chuah, Eric
    Cibulskis, Kristian
    Ciriello, Giovanni
    Clarke, Amanda
    Clayman, Gary L.
    Cope, Leslie
    Copland, John A.
    Covington, Kyle
    Danilova, Ludmila
    Davidsen, Tanja
    Demchok, John A.
    DiCara, Daniel
    Dhalla, Noreen
    [J]. CELL, 2014, 159 (03) : 676 - 690
  • [2] Novel therapeutic clues in thyroid carcinomas: The role of targeting cancer stem cells
    Antonelli, Alessandro
    La Motta, Concettina
    [J]. MEDICINAL RESEARCH REVIEWS, 2017, 37 (06) : 1299 - 1317
  • [3] TGF-β receptors: In and beyond TGF-β signaling
    Ark, Alexandra Vander
    Cao, Jingchen
    Li, Xiaohong
    [J]. CELLULAR SIGNALLING, 2018, 52 : 112 - 120
  • [4] Nomograms in oncology: more than meets the eye
    Balachandran, Vinod P.
    Gonen, Mithat
    Smith, J. Joshua
    DeMatteo, Ronald P.
    [J]. LANCET ONCOLOGY, 2015, 16 (04) : E173 - E180
  • [5] LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan
    Banerji, S
    Ni, J
    Wang, SX
    Clasper, S
    Su, J
    Tammi, R
    Jones, M
    Jackson, DG
    [J]. JOURNAL OF CELL BIOLOGY, 1999, 144 (04) : 789 - 801
  • [6] Subclinical Hyperthyroidism
    Biondi, Bernadette
    Cooper, David S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (25) : 2411 - 2419
  • [7] Thyroid cancer
    Cabanillas, Maria E.
    McFadden, David G.
    Durante, Cosimo
    [J]. LANCET, 2016, 388 (10061) : 2783 - 2795
  • [8] X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization
    Camp, RL
    Dolled-Filhart, M
    Rimm, DL
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (21) : 7252 - 7259
  • [9] Thyroid Cancer
    Carling, Tobias
    Udelsman, Robert
    [J]. ANNUAL REVIEW OF MEDICINE, VOL 65, 2014, 65 : 125 - 137
  • [10] Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis
    Chaib, H
    Cockrell, EK
    Rubin, MA
    Macoska, JA
    [J]. NEOPLASIA, 2001, 3 (01): : 43 - 52